Navigation Links
Cancer detection from an implantable, flexible LED
Date:9/19/2011

Daejeon, the Republic of Korea, August 8, 2011Can a flexible LED conformably placed on the human heart, situated on the corrugated surface of the human brain, or rolled upon the blood vessels, diagnose or even treat various diseases? These things might be a reality in the near future.

The team of Professor Keon Jae Lee (Department of Materials Science and Engineering, KAIST) has developed a new concept: a biocompatible, flexible Gallium Nitride (GaN) LED that can detect prostate cancer.

GaN LED, a highly efficient light emitting device, has been commercialized in LED TVs and in the lighting industry. Until now, it has been difficult to use this semiconductor material to fabricate flexible electronic systems due to its brittleness. The research team, however, has succeeded in developing a highly efficient, flexible GaN LED and in detecting cancer using a flexible LED biosensor.

Prof. Lee was involved in the first co-invention of "High Performance Flexible Single Crystal GaN" during his PhD course at the University of Illinois at Urbana-Champaign (UIUC). This flexible GaN LED biosensor utilized a similar protocol to transfer thin GaN LED films onto flexible substrates, followed by a biocompatible packaging process; the system's overall potential for use in implantable biomedical applications was demonstrated.

Professor John Roger (Department of Materials Science and Engineering, UIUC) said,

"Bio-integrated LEDs represent an exciting, new technology with strong potential to address important challenges in human health. This present work represents a very nice contribution to this emerging field."


'/>"/>

Contact: Lan Yoon
hlyoon@kaist.ac.kr
82-423-502-295
The Korea Advanced Institute of Science and Technology (KAIST)
Source:Eurekalert  

Page: 1

Related biology technology :

1. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
2. Some Patients Paying for Their Prostate Cancer Surgery for the Rest of Their Lives
3. OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
4. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
5. More Precise Prostate Cancer Screening on Horizon
6. New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology
7. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
8. Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
9. Novel Flavonoid Compounds That Significantly Reduce Cancer Cell Growth Are Available For Further Research and Development as Anti-Cancer Therapeutics
10. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
11. Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine -- Treatments Not Yet Offered in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer detection from an implantable, flexible LED
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):